Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free HIK Stock Alerts

Hikma Pharmaceuticals (HIK) Competitors

Hikma Pharmaceuticals logo
GBX 1,598 -31.00 (-1.90%)
As of 10:55 AM Eastern
Compare

HIK vs. DPH, INDV, HCM, VEC, and ERGO

Should you buy Hikma Pharmaceuticals stock or one of its competitors? Hikma Pharmaceuticals's main competitors and comparable companies include Dechra Pharmaceuticals (DPH), Indivior (INDV), HUTCHMED (HCM), Vectura Group (VEC), and Ergomed (ERGO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Hikma Pharmaceuticals compare to Dechra Pharmaceuticals?

Dechra Pharmaceuticals (LON:DPH) and Hikma Pharmaceuticals (LON:HIK) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

105.5% of Dechra Pharmaceuticals shares are held by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are held by institutional investors. 9.3% of Dechra Pharmaceuticals shares are held by company insiders. Comparatively, 22.3% of Hikma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hikma Pharmaceuticals has a consensus price target of GBX 2,085.83, indicating a potential upside of 28.04%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than Dechra Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dechra Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Hikma Pharmaceuticals has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dechra Pharmaceuticals£761.50M0.00-£27.90M-£0.25N/A
Hikma Pharmaceuticals£3.42B0.99£353.21M£176.009.26

Hikma Pharmaceuticals has a net margin of 11.31% compared to Dechra Pharmaceuticals' net margin of -3.66%. Hikma Pharmaceuticals' return on equity of 15.05% beat Dechra Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Dechra Pharmaceuticals-3.66% -3.92% 0.75%
Hikma Pharmaceuticals 11.31%15.05%9.40%

In the previous week, Hikma Pharmaceuticals had 4 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 4 mentions for Hikma Pharmaceuticals and 0 mentions for Dechra Pharmaceuticals. Hikma Pharmaceuticals' average media sentiment score of 0.30 beat Dechra Pharmaceuticals' score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Dechra Pharmaceuticals Neutral
Hikma Pharmaceuticals Neutral

Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. Hikma Pharmaceuticals pays an annual dividend of GBX 82.48 per share and has a dividend yield of 5.1%. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. Hikma Pharmaceuticals pays out 46.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Dechra Pharmaceuticals has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Hikma Pharmaceuticals has a beta of 0.662, indicating that its share price is 34% less volatile than the broader market.

Summary

Hikma Pharmaceuticals beats Dechra Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Indivior?

Hikma Pharmaceuticals (LON:HIK) and Indivior (LON:INDV) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Hikma Pharmaceuticals has a net margin of 11.31% compared to Indivior's net margin of 0.17%. Hikma Pharmaceuticals' return on equity of 15.05% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Hikma Pharmaceuticals11.31% 15.05% 9.40%
Indivior 0.17%-1.11%2.37%

In the previous week, Hikma Pharmaceuticals had 4 more articles in the media than Indivior. MarketBeat recorded 4 mentions for Hikma Pharmaceuticals and 0 mentions for Indivior. Hikma Pharmaceuticals' average media sentiment score of 0.30 beat Indivior's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Hikma Pharmaceuticals Neutral
Indivior Neutral

Hikma Pharmaceuticals has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£3.42B0.99£353.21M£176.009.26
Indivior£1.40B1.38-£2.36M-£1.21N/A

Hikma Pharmaceuticals pays an annual dividend of GBX 82.48 per share and has a dividend yield of 5.1%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. Hikma Pharmaceuticals pays out 46.9% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Hikma Pharmaceuticals currently has a consensus price target of GBX 2,085.83, indicating a potential upside of 28.04%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Hikma Pharmaceuticals is more favorable than Indivior.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Indivior
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Hikma Pharmaceuticals has a beta of 0.662, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.0% of Indivior shares are owned by institutional investors. 22.3% of Hikma Pharmaceuticals shares are owned by company insiders. Comparatively, 3.4% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Hikma Pharmaceuticals beats Indivior on 15 of the 18 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to HUTCHMED?

HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

HUTCHMED has a beta of 0.428, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Hikma Pharmaceuticals has a beta of 0.662, suggesting that its stock price is 34% less volatile than the broader market.

HUTCHMED has a net margin of 163.84% compared to Hikma Pharmaceuticals' net margin of 11.31%. HUTCHMED's return on equity of 18.42% beat Hikma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED163.84% 18.42% -5.90%
Hikma Pharmaceuticals 11.31%15.05%9.40%

In the previous week, Hikma Pharmaceuticals had 4 more articles in the media than HUTCHMED. MarketBeat recorded 4 mentions for Hikma Pharmaceuticals and 0 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.30 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
HUTCHMED Neutral
Hikma Pharmaceuticals Neutral

20.7% of HUTCHMED shares are owned by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by company insiders. Comparatively, 22.3% of Hikma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£549.12M3.40-£52.98M£2.00107.50
Hikma Pharmaceuticals£3.42B0.99£353.21M£176.009.26

Hikma Pharmaceuticals has a consensus price target of GBX 2,085.83, suggesting a potential upside of 28.04%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Hikma Pharmaceuticals beats HUTCHMED on 12 of the 16 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Vectura Group?

Vectura Group (LON:VEC) and Hikma Pharmaceuticals (LON:HIK) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Hikma Pharmaceuticals has a net margin of 11.31% compared to Vectura Group's net margin of 0.00%. Hikma Pharmaceuticals' return on equity of 15.05% beat Vectura Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Vectura GroupN/A N/A N/A
Hikma Pharmaceuticals 11.31%15.05%9.40%

In the previous week, Hikma Pharmaceuticals had 4 more articles in the media than Vectura Group. MarketBeat recorded 4 mentions for Hikma Pharmaceuticals and 0 mentions for Vectura Group. Hikma Pharmaceuticals' average media sentiment score of 0.30 beat Vectura Group's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Vectura Group Neutral
Hikma Pharmaceuticals Neutral

Vectura Group pays an annual dividend of GBX 38 per share. Hikma Pharmaceuticals pays an annual dividend of GBX 82.48 per share and has a dividend yield of 5.1%. Vectura Group pays out 189.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hikma Pharmaceuticals pays out 46.9% of its earnings in the form of a dividend. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

Hikma Pharmaceuticals has a consensus price target of GBX 2,085.83, indicating a potential upside of 28.04%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than Vectura Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vectura Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Hikma Pharmaceuticals has higher revenue and earnings than Vectura Group. Vectura Group is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vectura Group£190.60M0.00N/A£20.10N/A
Hikma Pharmaceuticals£3.42B0.99£353.21M£176.009.26

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. 22.3% of Hikma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Hikma Pharmaceuticals beats Vectura Group on 15 of the 15 factors compared between the two stocks.

How does Hikma Pharmaceuticals compare to Ergomed?

Hikma Pharmaceuticals (LON:HIK) and Ergomed (LON:ERGO) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Hikma Pharmaceuticals presently has a consensus target price of GBX 2,085.83, indicating a potential upside of 28.04%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than Ergomed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ergomed
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 22.3% of Hikma Pharmaceuticals shares are owned by company insiders. Comparatively, 18.2% of Ergomed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Hikma Pharmaceuticals has a beta of 0.662, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Hikma Pharmaceuticals has a net margin of 11.31% compared to Ergomed's net margin of 9.87%. Ergomed's return on equity of 18.08% beat Hikma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hikma Pharmaceuticals11.31% 15.05% 9.40%
Ergomed 9.87%18.08%10.16%

In the previous week, Hikma Pharmaceuticals had 4 more articles in the media than Ergomed. MarketBeat recorded 4 mentions for Hikma Pharmaceuticals and 0 mentions for Ergomed. Hikma Pharmaceuticals' average media sentiment score of 0.30 beat Ergomed's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Hikma Pharmaceuticals Neutral
Ergomed Neutral

Hikma Pharmaceuticals has higher revenue and earnings than Ergomed. Ergomed is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£3.42B0.99£353.21M£176.009.26
Ergomed£152.09M0.00£15M£0.29N/A

Summary

Hikma Pharmaceuticals beats Ergomed on 10 of the 15 factors compared between the two stocks.

Get Hikma Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HIK vs. The Competition

Export
MetricHikma PharmaceuticalsPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£3.35B£12.26B£7.20B£2.82B
Dividend Yield3.99%2.63%2.52%6.26%
P/E Ratio9.19800.08275.27367.19
Price / Sales0.98926.40621.3588,447.52
Price / Cash8.3415.2827.3027.87
Price / Book1.578.9310.587.00
Net Income£353.21M£2.82B£3.49B£5.89B
7 Day Performance-0.12%-2.45%-2.10%0.01%
1 Month Performance5.68%-5.22%-5.65%-0.48%
1 Year Performance-10.11%-4.97%4.88%22.67%

Hikma Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HIK
Hikma Pharmaceuticals
4.5606 of 5 stars		GBX 1,598
-1.9%		GBX 2,085.83
+30.5%		-10.9%£3.31B£3.42B9.089,500
DPH
Dechra Pharmaceuticals
N/AN/AN/AN/A£4.40B£761.50MN/A2,457
INDV
Indivior
N/AGBX 1,238
+1.6%		N/A+0.0%£1.93B£1.40BN/A1,000
HCM
HUTCHMED
N/AGBX 220
-0.5%		N/A-8.9%£1.91B£549.12M110.001,760
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HIK) was last updated on 10/13/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel